AIP
ALGS icon

Ameritas Investment Partners’s Aligos Therapeutics ALGS Stock Holding History

Ameritas Investment Partners’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-59
Closed -$3K – 3061
2022
Q1 		$3K Hold
59
– – ﹤0.01% 3021
2021
Q4 		$17K Hold
59
– – ﹤0.01% 2703
2021
Q3 		$23K Hold
59
– – ﹤0.01% 2616
2021
Q2 		$30K Buy
59
+25
+74% +$15.9K ﹤0.01% 2495
2021
Q1 		$19K Hold
34
– – ﹤0.01% 2576
2020
Q4 		$23K Buy
+34
New +$16.6K ﹤0.01% 2396

Other funds holding ALGS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ameritas Investment Partners's ALGS Position: Q2 2022 in Review

Ameritas Investment Partners sold out of Aligos Therapeutics (ALGS) in Q2 2022, closing a stake of 59 shares — an estimated $3K sold.

Ameritas Investment Partners first reported a position in ALGS in Q4 2020 and held it in 6 quarters. The position peaked at $30K in Q2 2021. 59 funds tracked by Wall St. Rank hold ALGS as of Q2 2022.

  • Ameritas Investment Partners reported no remaining Aligos Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Ameritas Investment Partners sold 59 Aligos Therapeutics shares in Q2 2022, an estimated $3K.
  • Ameritas Investment Partners first reported a position in Aligos Therapeutics in Q4 2020 and held it in 6 quarters.
  • Ameritas Investment Partners's Aligos Therapeutics position peaked at $30K in Q2 2021.
  • 59 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2022.

Based on Ameritas Investment Partners's 13F filing for Q2 2022, filed 12 Aug 2022.